https://www.optimumcomms.com/wp-content/uploads/2023/12/Vesper_Bio_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-05-09 08:39:022025-05-09 08:39:02Vesper Bio achieves enrolment milestone in Phase Ib/IIa trial of lead candidate VES001 for frontotemporal dementia
https://www.optimumcomms.com/wp-content/uploads/2023/12/Vesper_Bio_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-05-09 08:39:022025-05-09 08:39:02Vesper Bio achieves enrolment milestone in Phase Ib/IIa trial of lead candidate VES001 for frontotemporal dementia
https://www.optimumcomms.com/wp-content/uploads/2024/06/iOnctura_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-05-08 09:06:512025-05-08 09:06:51iOnctura commences randomized Phase I/II study in non-small cell lung cancer
https://www.optimumcomms.com/wp-content/uploads/2023/02/Alchemab_Logo_300px-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-05-06 08:42:372025-05-06 08:42:37Alchemab Therapeutics signs landmark $415m licensing agreement for ATLX-1282 with Eli Lilly and Company
https://www.optimumcomms.com/wp-content/uploads/2023/08/Astraveus.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-05-06 08:34:012025-05-06 08:34:01Astraveus Enters Strategic Partnership with NecstGen to evaluate Lakhesys Benchtop Cell FactoryTM for CAR-T therapy manufacturing
https://www.optimumcomms.com/wp-content/uploads/2025/02/Domain_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-04-30 08:33:012025-04-30 08:33:01Domain Therapeutics Presents Novel Data Addressing Key Challenges in Oncology at AACR 2025
https://www.optimumcomms.com/wp-content/uploads/2023/06/NovoFund_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-04-29 08:42:482025-04-29 08:45:51Novo Nordisk Foundation expands Challenge Programme outside of Denmark for the first time and significantly increases grants
https://www.optimumcomms.com/wp-content/uploads/2025/04/CyCuria_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-04-28 09:14:072025-04-28 10:41:30Cycuria Therapeutics Launches with the Formation of a Distinguished Advisory Board and Significant Public Grant Funding
https://www.optimumcomms.com/wp-content/uploads/2025/03/Novo_Holdings23_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-04-24 10:54:132025-04-24 10:54:13Novo Holdings and EIFO invest €48 million in HealthCap IX to strengthen the Nordic life sciences ecosystem
https://www.optimumcomms.com/wp-content/uploads/2024/03/Heidelberg_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-04-24 08:30:382025-04-24 08:30:38Heidelberg Pharma AG: Interim Statement on the First Three Months of Financial Year 2025
https://www.optimumcomms.com/wp-content/uploads/2025/04/Alis-Biosciences_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-04-18 08:08:372025-04-18 15:50:28Alis Biosciences launches fund to free over USD$30 billion of capital trapped in listed development-stage life sciences and biotech companies
https://www.optimumcomms.com/wp-content/uploads/2023/08/Astraveus.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-04-15 08:33:112025-04-15 08:33:11Astraveus Strengthens Leadership Team and Board
https://www.optimumcomms.com/wp-content/uploads/2023/10/Oxolife_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-04-09 12:59:372025-04-09 12:59:37Oxolife’s CEO Agnès Arbat receives prestigious EU Women Innovators Prize
https://www.optimumcomms.com/wp-content/uploads/2024/11/Infinitopes_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-04-09 10:33:472025-04-09 10:33:47Infinitopes Granted Phase I/IIa Clinical Trial Application Approval to Evaluate Precision Vaccine Targeting Early-Stage Oesophageal Cancer
https://www.optimumcomms.com/wp-content/uploads/2024/04/Xeltis_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-04-08 08:34:372025-04-08 09:54:08Xeltis successfully passes evaluation phase for €10million investment from European Innovation Council
https://www.optimumcomms.com/wp-content/uploads/2025/03/Novo_Holdings23_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-04-02 09:10:232025-04-02 09:10:23Novo Holdings posts record Total Income and Investment Returns of DKK 60 billion (€8.0 billion) in 2024, with the Investment Portfolio delivering above-benchmark returns, alongside strong growth at the Novo Group companies
https://www.optimumcomms.com/wp-content/uploads/2025/02/Domain_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-04-01 08:31:232025-04-01 08:31:23Domain Therapeutics to Present Data on its GPCR Lead Programs at AACR Annual Meeting 2025We’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
